NCT05590338View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

July 12, 2023

Study Completion Date

December 28, 2023

Conditions
Dermatitis, Atopic
Interventions
DRUG

GSK1070806

Participants will receive GSK1070806

DRUG

Placebo

Participants will receive placebo

Trial Locations (2)

89113

GSK Investigational Site, Las Vegas

90630

GSK Investigational Site, Cypress

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY